Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial

E. Bel (Amsterdam, Netherlands), W. Moore (Winston-Salem, NC, United States of America), O. Kornmann (Frankfurt, Germany), C. Poirier (Montreal, QC, Canada), N. Kaneko (Kamogawa, Japan), S. Smith (Research Triangle Park, NC, United States of America), N. Martin (Brentford, Middlesex and Leicester, United Kingdom), M. Gilson (Uxbridge, Middlesex, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), E. Bradford (Research Triangle Park, NC, United States of America), M. Humbert (Paris, France)

Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Session: Recent innovations regarding the mechanisms and treatments of asthma
Session type: Oral Presentation
Number: 5280

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Bel (Amsterdam, Netherlands), W. Moore (Winston-Salem, NC, United States of America), O. Kornmann (Frankfurt, Germany), C. Poirier (Montreal, QC, Canada), N. Kaneko (Kamogawa, Japan), S. Smith (Research Triangle Park, NC, United States of America), N. Martin (Brentford, Middlesex and Leicester, United Kingdom), M. Gilson (Uxbridge, Middlesex, United Kingdom), R. Price (Stevenage, Hertfordshire, United Kingdom), E. Bradford (Research Triangle Park, NC, United States of America), M. Humbert (Paris, France). Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial. 5280

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: